help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2007-0938
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
92/12/4590    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oudoux, A.
Right arrow Articles by Kraeber-Bodéré, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oudoux, A.
Right arrow Articles by Kraeber-Bodéré, F.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Thyroid Cancer
Related Collections
Right arrow Thyroid
Right arrow Endocrine Oncology
The Journal of Clinical Endocrinology & Metabolism Vol. 92, No. 12 4590-4597
Copyright © 2007 by The Endocrine Society

Sensitivity and Prognostic Value of Positron Emission Tomography with F-18-Fluorodeoxyglucose and Sensitivity of Immunoscintigraphy in Patients with Medullary Thyroid Carcinoma Treated with Anticarcinoembryonic Antigen-Targeted Radioimmunotherapy

Aurore Oudoux, Pierre-Yves Salaun, Claire Bournaud, Loïc Campion, Catherine Ansquer, Caroline Rousseau, Stéphane Bardet, Françoise Borson-Chazot, Jean-Philippe Vuillez, Arnaud Murat, Eric Mirallié, Jacques Barbet, David M. Goldenberg, Jean-François Chatal and Françoise Kraeber-Bodéré

Nuclear Medicine (A.O., C.A., F.K.-B.), Endocrinology (A.M.), and Endocrine Surgery (E.M.) Departments, University Hospital, 44093 Nantes, France; Nuclear Medicine (P.-Y.S., C.R., F.K.-B.) and Statistic (L.C.) Departments, René Gauducheau Cancer Center, 44805 Nantes, France; Nuclear Medicine Department (C.B., F.B.-C.), University Hospital, 69495 Lyon, France; Nuclear Medicine Department (S.B.), François Baclesse Cancer Center, 14076 Caen, France; Nuclear Medicine Department (J.-P.V.), University Hospital, 38043 Grenoble, France; Oncology Research Department (J.B., J.-F.C., F.K.-B.), Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche 601, 44093 Nantes, France; and Garden State Cancer Center (D.M.G.), Center for Molecular Medicine and Immunology, Belleville, New Jersey 07109-0023

Address all correspondence and requests for reprints to: Françoise Kraeber-Bodéré, Oncology Research Department, Institut National de la Santé et de la Recherche Médicale U601, Institut de Biologie, 9 quai Moncousu, 44093 Nantes Cedex 1, France. E-mail: francoise.bodere{at}chu-nantes.fr.

Context: Patients with progressive medullary thyroid carcinoma (MTC) undergo multiple imaging procedures for diagnosis of relapse and staging.

Objective: Our objective was to assess the sensitivity and prognostic value of 18F-2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET)/computed tomography (CT), and the imaging sensitivity of pretargeted iodine-131-radioimmunotherapy (RIT) in patients with progressive MTC.

Design/Setting/Patients: We performed a prospective multicenter study in high-risk patients with rapidly progressing MTC enrolled in a phase-II pretargeted RIT study, as documented by short serum calcitonin (Ct) or carcinoembryonic antigen (CEA) doubling time (DT).

Interventions/Main Outcome Measures: Patients underwent neck-thoracic-abdominal CT, spine and pelvic magnetic resonance imaging, whole-body post-RIT immunoscintigraphy (IS) with iodine-131, and whole-body 18F-FDG-PET/CT imaging. Imaging sensitivity and the correlation between FDG uptake and biomarkers DT were evaluated.

Results: A total of 33 patients with mean CEA and Ct DTs of 1.90 yr (range 0.21–8.50) and 1.52 yr (range 0.09–6.01), respectively, were evaluated. Sensitivity of FDG-PET/CT was 83% for neck, 85% for mediastinal, 75% for lung, 60% for liver, and 67% for bone metastases; overall sensitivity was 76%. Median standardized uptake value (SUVmax) was 5.23 (2.06–13.90). SUVmax correlated significantly with Ct DT (P = 0.011) and minimal DT (minimal value between CEA DT and Ct DT) (P = 0.027). Overall sensitivity of post-RIT IS, CT, and bone magnetic resonance imaging were 94, 74, and 85%, respectively.

Conclusions: These results demonstrate the value of FDG-PET/CT for staging of patients with progressive MTC, especially in the neck and mediastinum, with possible prognostication by SUV quantification. Post-RIT IS was the most sensitive of the imaging modalities studied prospectively.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society